Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $43.9 million.

  • Insight Molecular Diagnostics' Other Non-Current Liabilities fell 977.89% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year decrease of 977.89%. This contributed to the annual value of $37.7 million for FY2024, which is 548.62% down from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Other Non-Current Liabilities stood at $43.9 million, which was down 977.89% from $40.9 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Other Non-Current Liabilities' 5-year high stood at $76.7 million during Q4 2021, with a 5-year trough of $8.2 million in Q1 2021.
  • In the last 5 years, Insight Molecular Diagnostics' Other Non-Current Liabilities had a median value of $42.7 million in 2024 and averaged $42.7 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 97698.03% in 2021, then plummeted by 8454.7% in 2023.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Other Non-Current Liabilities stood at $76.7 million in 2021, then tumbled by 40.45% to $45.7 million in 2022, then decreased by 12.62% to $39.9 million in 2023, then fell by 5.49% to $37.7 million in 2024, then increased by 16.53% to $43.9 million in 2025.
  • Its Other Non-Current Liabilities was $43.9 million in Q3 2025, compared to $40.9 million in Q2 2025 and $38.4 million in Q1 2025.